Dr. Friedman has proven experience in drug development working with leaders in the pharmaceutical industry, Food and Drug Administration, National Cancer Institute and advocacy groups. He is a seasoned innovator and team builder who has built organization cultures for new products and therapy development. He is an expert connector with a network of decision makers in a broad spectrum of industries including financial/banking, healthcare, health insurance, sports media, federal, legal and political.
Dr. Friedman is a committed educator who is a member of the Executive and Super Executive Committees of Duke Medical School which is responsible for the recruitment, screening and selection of medical students. He has reviewed grants for the National Institutes of Health for over 15 years in a spectrum of different study sections. He is the senior editor of CNS Oncology, was the Associate Editor for the Neuro-Oncology Section of Cancer for 15 years and is a reviewer for over 25 academic journals.
Dr. Friedman serves on the advisory board of a number of organizations including The Musella Foundation For Brain Tumor Research & Information, Inc, Voices Against Brain Cancer, the Tug McGraw Foundation, Pinnacle Care, Transforming Medicine, the National Children's Cancer Society, American Brain Tumor Association and Cancer Expert Now. He is on the Board of Directors of TEAM Doctors Preferred Access, the Michael Mosier Defeat DIPG Foundation and the Foundation for Biomedical Research. He has received a number of awards for his work including the Visionary Award from the Tug McGraw Foundation, the Gary Lichtenstein Humanitarian Award from the Voices Against Brain Cancer Foundation and the Healthnetwork Foundation Service Excellence Award. He is a member of the American Society of Clinical Investigation.
